Advantages of the Vaxart Vaccine Platform

• New vaccines can be created very quickly to protect against new circulating avian flu strains, other emerging pathogens, or bioterror threats- using straightforward molecular biology.
  
  
• Vaxart never needs to culture or attenuate a pathogen, or develop new recombinant protein antigens.
  
  
• Vaxart uses efficient and standardized cell culture manufacturing methods, with essentially the same process for every Vaxart vaccine.
  
  
• Vaxart vaccines generate antigen-specific killer T-cell responses as well as antibody responses.
  
  
• Oral delivery is strongly preferred by care providers and patients.
  
  
• Oral vaccination with live adenovirus has an excellent safety record (Adenovirus type 4,7 vaccine was approved by FDA and given to millions of military recruits to prevent respiratory infections).

News

November 2007: Vaxart (fka West Coast Biologicals) Completes Series A Financing. Read more...

May 2007: Dr. Sean Tucker of West Coast Biologicals presents data on the oral adenovirus vaccine platform at the Center of Business Intelligence's Vaccine Development Summit, Philadelphia, PA. Learn about CBI's elite speakers and order meeting CD.

November 2006: Target World Drug Delivery News publishes profile of West Coast Biologicals as Emerging Company (Nov 2006 issue 59).

September 2006: West Coast Biologicals presents data on oral adenovirus vaccines at Modern Vaccines Adjuvants & Delivery Systems conference in London. Read more...

April 2006: West Coast Biologicals is a finalist in the 2006 Global Life Sciences Innovation Accelerator Competition at UCSF. Learn more about the Life Science Innovation Competition...